The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sorry for double post. Don’t know how that happened!
NDN, asthma trial didn’t meet its primary endpoint but when they looked at subgroups was shown to be show significant effect in the exacerbating patients. COPD trial the same. I agree P2 covid home trial was statistically underpowered.
The point is the P3 hostpital trial has been set up to focus on those patients that SNG know they have seen a statistical positive effect in previous trials.
Activ 2 home trial is completely different as it’s a cohort of patients that SNG has never been trialled in previously, apart from a small underpowered trial. It may be found to be a very useful drug early in disease but the company has no idea on this. If the investment descion was based solely around a result in activ 2 this would be a much riskier proposition, but the P3 hospital trial is set up for success reducing risk dramatically.
NDN, asthma trial didn’t meet its primary endpoint but when they looked at subgroups was shown to be show significant effect in the exacerbating patients. COPD trial the same. I agree P2 covid home trial was statistically underpowered.
The point is the P3 hostpital trial has been set up to focus on those patients that SNG know they have seen a statistical positive effect in previous trials.
Activ 2 home trial is completely different as it’s a cohort of patients that SNG has never been trialled in previously, apart from a small underpowered trial. It may be found to be a very useful drug early in disease but the company has no idea on this. If the investment descion was based solely around a result in activ 2 this would be a much riskier proposition, but the P3 hospital trial is set up for success reducing risk dramatically.
Everything about SNG001 and its action makes sense to me. The drug works to effectively boost the immune response, seemingly because of the role that the body's interferons have in that response. If we could easily determine those whose immune response level is compromised beyond age, diabetes etc, then we could choose those people to treat early in their infection story. However, breathlessness seems to be the only measurement available at this stage that indicates a compromised immune response, hence SNG001 's success in these patients. The logic of this is the reason that I remain invested, as well as the fact that it is not just a Covid treatment.:)
The actual whole premise of the article is completely wrong around timing of when to use then drug on the P3
SNG over multiple trials and multiple diseases have narrowed down the clinical situation of when the drug works best ie. in breathless patients requiring oxygen. If you don’t believe this go back and read the data readout for the SNG asthma, COPD, and covid P2 trials. I did it last week prior to this uninformed and actually nonsensical article.
SNG set up their P3 trial so the actual timing of when to give P3 is exactly when they know they have seen the biggest effect in previous clinical trial. It is for this reason that timing of when to give the drug in the P3 is a completely non issue.
It’s likely many individuals involved with this article have a conflict of interest.
For me the fact they say SNG001 has a place at all as a therapeutic means it was likely a resounding success in all trials to date……..
GLA
Spot on CC.
You're most welcome to repost / try to amplify "News" (it wasn't a news piece)
This was a "for hire" hatchet job by someone without credibility of biopharmacutical matters. 45 minutes in front of a computer with a Google search Could have produced a more meaningful and technically coherent piece. I'd not be surprised to find the little toe rag write in The Motley Fool, they tend to hire similar dross. He makes no mention of Dr Fish and her conflict of interest which makes me think he's taken some of her words well out of context and not directly quoted her.
Allow me to re-amplify my earlier response as that seems to be the method the paid for bashers are trying...
RE: clinical trialsSat 06:12
Regarding the Article attributed to Dr Fish.
Written by a "journalist" call Adam Zamecnik. Looks like a "for hire" hatchet number. Not a medical specialist :
hTtps://muckrack.com/adam-zamecnik
This was a poorly written piece aimed at casting doubt on the efficacy of Inhaled Interferon Beta 1a probably to destabilise the share price.
Phrases like "experts say" in the first section then a second section name dropping Dr Fish to give the article a sense of gravitas and authenticity are inconsistent
The de-ramping by paid for bashers is a strong buy signal. Don't be fooled, they want your shares folks and they don't care how they get them.